611168-85-5

Basic information

• Product Name: 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea
• Synonyms: 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea
• CAS NO: 611168-85-5
• Molecular Weight: 558.637
• Mol File: 611168-85-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea(611168-85-5)
• EPA Substance Registry System: 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea(611168-85-5)

Safety Data

• Hazardous Substances Data: 611168-85-5(Hazardous Substances Data)

Upstream product

• 317806-90-9 4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-ylamine 
• 611168-84-4 [5-tert-butyl-2-(3-nitrophenyl)-2H-pyrazol-3-yl]-carbamic acid phenyl ester 
• 476637-05-5 2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl-amine 
• 1012883-12-3 C₁₆H₁₇Cl₃N₄O₄ 
• 317806-89-6 C₁₆H₂₀N₂O₂*ClH 

Downstream Products

• 1609257-17-1 1-(3-(tert-butyl)-1-(3-((2-ethoxyethyl)amino)phenyl)-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea 

Relevant articles and documents

Identification of type II and III DDR2 inhibitors

Discoidin domain-containing receptors (DDRs) exhibit a unique mechanism of action among the receptor tyrosine kinases (RTKs) because their catalytic activity is induced by extracellular collagen binding. Moreover, they are essential components in the assimilation of extracellular signals. Recently, DDRs were reported to be significantly linked to tumor progression in breast cancer by facilitating the processes of invasion, migration, and metastasis. Here, we report the successful development of a fluorescence-based, direct binding assay for the detection of type II and III DFG-out binders for DDR2. Using sequence alignments and homology modeling, we designed a DDR2 construct appropriate for fluorescent labeling. Successful assay development was validated by sensitive detection of a reference DFG-out binder. Subsequent downscaling led to convenient application to high-throughput screening formats. Screening of a representative compound library identified high-affinity DDR2 ligands validated by orthogonal activity-based assays, and a subset of identified compounds was further investigated with respect to DDR1 inhibition.